Clinical Trial Update: A BCG Challenge Model Study to Assess Anti-mycobacterial Immunity Induced by BCG and a Candidate TB Vaccine, MVA85A [Phase 1]

View source ↗

Summary

This completed Phase 1 study evaluated anti-mycobacterial immune responses induced by BCG and the candidate TB vaccine MVA85A using a BCG challenge model.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• BCG vaccine (Bacillus Calmette-Guérin)
• MVA85A (Modified Vaccinia Ankara expressing antigen 85A)

Snippet

Sponsor: University of Oxford | Conditions: Tuberculosis | Phase 1 | Status: COMPLETED